Zydus Lifesciences Limited (NSE:ZYDUSLIFE)
India · Delayed Price · Currency is INR | Market Cap | 1.08T +15.1% |
| Revenue (ttm) | 271.48B +16.8% |
| Net Income | 50.40B +11.4% |
| EPS | 50.09 +11.4% |
| Shares Out | 1.01B |
| PE Ratio | 21.38 |
| Forward PE | 26.00 |
| Dividend | 1.00 (0.09%) |
| Ex-Dividend Date | Jul 24, 2026 |
| Volume | 887,225 |
| Open | 1,074.40 |
| Previous Close | 1,074.40 |
| Day's Range | 1,065.00 - 1,083.00 |
| 52-Week Range | 835.50 - 1,119.80 |
| Beta | 0.40 |
| Analysts | Hold |
| Price Target | 1,066.50 (-0.4%) |
| Earnings Date | Aug 7, 2026 |
About Zydus Lifesciences
Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It operates through two segments: Pharmaceuticals and Consumer Products. It offers active pharmaceutical ingredients, finished dosage formulations, generics, specialty, biosimilars, vaccines, novel products, consumer wellness and animal health products under the Everyuth, Nutralite, SugarFree, Complan, Glucon-D, and Nycil brands. The company also provides a pi... [Read more]
Financial Performance
In fiscal year 2026, Zydus Lifesciences's revenue was 271.48 billion, an increase of 16.81% compared to the previous year's 232.42 billion. Earnings were 50.40 billion, an increase of 11.37%.
Financial StatementsAnalyst Summary
According to 30 analysts, the average rating for ZYDUSLIFE stock is "Hold." The 12-month stock price target is ₹1,067, which is a decrease of -0.40% from the latest price.
News
Zydus Lifesciences sees significant buyback participation from promoters
Zydus Lifesciences Limited has disclosed substantial participation in its equity share buyback programme by its promoters and promoter group. The buyback involved equity shares of Re. 1 each, accepted...
Zydus Lifesciences completes Rs 1,100 crore buyback extinguishing over 87 lakh shares
Zydus Lifesciences Limited has successfully completed a buyback of 87,30,158 equity shares, each with a face value of ₹1, at a price of ₹1,260 per share. The total buyback size…
Top stocks for trade today, June 17: Infosys, Wipro, TCS, Zydus Lifesciences, Bharat Forge and more
Several stocks are expected to remain in focus on June 17 following key corporate announcements, strategic partnerships, acquisitions, buybacks, management changes, fundraising activities, and regulat...
Zydus Lifesciences completes merger with Assero Holdings for USD 166.33 million
Zydus Lifesciences Limited has successfully completed the merger of its acquisition subsidiary, Zara Merger Sub Inc., with Assero Holdings Inc., making Assero a wholly owned subsidiary of the company....
Zydus completes acquisition of Assertio Holdings for $23.50 per share
Zydus Lifesciences Ltd. has successfully completed the acquisition of Assertio Holdings, Inc. through a cash tender offer. The purchase was executed via Zydus's wholly-owned subsidiary, Zara Merger Su...
Zydus Lifesciences reports significant reduction in GST demand for subsidiary
Zydus Lifesciences Limited has announced a favourable outcome in the Goods and Services Tax (GST) demand case involving its wholly owned subsidiary, Zydus Healthcare Limited (ZHL). The Appellate Addit...
Zydus Lifesciences receives USFDA warning letter for Baddi manufacturing facility
Zydus Lifesciences has informed stock exchanges that it has received a Warning Letter from the United States Food and Drug Administration (USFDA) concerning its formulation manufacturing facility loca...
Pharma sector stocks today, June 3: Natco Pharma falls 2.57%, Zydus Lifesciences falls 1.26%, Alembic Pharma down 1.06%
Pharmaceutical stocks traded mixed on June 3, 2026, during the morning session. While a few stocks posted modest gains, several others witnessed selling pressure. The BSE Healthcare index declined 0.2...
Pharma sector stocks today, May 22: Aurobindo Pharma falls 4.11%, Zydus Lifesciences rises 0.92%, Alembic Pharma up 1.06%
Pharmaceutical stocks traded mixed on May 22, 2026, during the morning session. While some stocks posted modest gains, a few names, including Aurobindo Pharma, witnessed sharp declines. The BSE Health...
Buyback Calendar for May 2026: Zydus Lifesciences, Wipro, Bajaj Auto, Cyient among stocks in focus
Several listed companies have announced share buybacks for May 2026, with investors closely tracking record dates, buyback prices, and the gap between current market price (CMP) and offer price. Compa...
Zydus Lifesciences finalises equity subscription in Torrent Urja 25
Zydus Lifesciences Ltd has completed its planned equity investment in Torrent Urja 25 Private Limited, the company informed stock exchanges on May 20, 2026. The pharmaceutical major said the transacti...
Pharma Stocks Today, May 20: Zydus Lifesciences jumps 5.22%, Mankind Pharma rises 2.52%, Strides Pharma up 1.85%
Pharmaceutical stocks opened on a mixed note on May 20 2026 during the early morning session. While several stocks posted strong gains, a few names traded lower. The BSE Healthcare…
Zydus Lifesciences Earnings Call Transcript: Q4 2026
Delivered record revenue and profit growth in FY 2026, driven by strong performance across U.S., India, and international markets, with robust margins and successful integration of acquisitions. FY 2027 guidance calls for high teens revenue growth and EBITDA margin above 24%.
Zydus Lifesciences Quarterly report: Q4 2026
Zydus Lifesciences has published its Q4 2026 quarterly earnings report on May 19, 2026.
Zydus Lifesciences Slides: Q4 2026
Zydus Lifesciences has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on May 19, 2026.
Why are Zydus Lifesciences shares up 6% today? Here’s what’s driving the rally
Shares of Zydus Lifesciences Ltd surged over 6% in Tuesday’s trade after the pharmaceutical major announced a ₹1,100 crore share buyback alongside strong March quarter earnings. The stock climbed as…
Zydus Lifesciences announces ₹1,100 crore buyback at 12.7% premium
Zydus Lifesciences along with its Q4 results today approved a share buyback worth up to ₹1,100 crore at a price of ₹1,150 per equity share, representing a premium of nearly…
Zydus Life Q4 Results: Net profit rises 9% as EBITDA margin improves to 33.7%
Zydus Lifesciences Ltd reported a healthy operational performance for the quarter ended March 31, 2026, driven by strong revenue growth and margin expansion. The company posted a consolidated net prof...
Top Q4 results today, May 19: Bharat Electronics, Bharat Petroleum Corporation, Zydus Lifesciences, Alembic among key companies to announce earnings
More than 125 companies are scheduled to announce their Q4FY26 results on May 19, making it one of the busiest earnings days of the season. Major companies from sectors including…
Pharma sector stocks today, May 14: Cipla jumps 7.15%, Zydus Lifesciences rises 4.01%, Strides Pharma up 2.20%
Pharmaceutical stocks opened strongly on May 14 2026 during the early morning trading session. The sector witnessed broad-based buying interest with most stocks trading in the green. The BSE Healthcar...
Assertio Terminates Garda Agreement, Agrees To $166.4 Mln Acquisition By Zydus Worldwide DMCC
(RTTNews) - Assertio Holdings, Inc. (ASRT), on Wednesday, announced that Zydus Worldwide DMCC, a subsidiary of Zydus Lifesciences Ltd. (ZYDUSLIFE.BO, ZYDUSLIFE.NS), agreed to acquire Assertio for appr...
Pharma sector stocks today, April 30: Biocon falls 1.01%, Torrent Pharma down 0.95%, Zydus Lifesciences drops 0.85%
Indian pharmaceutical stocks opened the last trading session of April 2026 on a broadly weak note, with the majority of pharma scrips trading in the red in early trade. The…
Zydus Life shares in focus as USFDA clears Ahmedabad oncology facility; receives EIR for injectable plant
Zydus Lifesciences Limited has received the Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for its oncology injectable manufacturing facility at SEZ-1, Ahmedaba...
New Diabetes Generic Drug Gets Approval In US Market: All About Dapagliflozin
Zydus Lifesciences has received USFDA approval for generic dapagliflozin tablets used to treat type 2 diabetes. Here's how the drug works, its benefits, and why it is important for blood sugar control...
Zydus Lifesciences reports insider trading violation involving Rs 9,027 transaction
Zydus Lifesciences Limited has reported a violation of the Code of Conduct under the SEBI (Prohibition of Insider Trading) Regulations, 2015. The breach involved a designated person, Mr. Debtaru Upadh...